Supplementary Data1 from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer
| Title: | Supplementary Data1 from Phase Ib Trial of Fulvestrant, Palbociclib, and Erdafitinib, a pan-FGFR Tyrosine Kinase Inhibitor, in HR+/HER2− Metastatic Breast Cancer |
|---|---|
| Authors: | Paula I. Gonzalez-Ericsson; Nisha Unni; Komal Jhaveri; Erica Stringer-Reasor; Qi Liu; Yu Wang; Violeta Sanchez; Guadalupe Garcia; Melinda E. Sanders; Brian D. Lehmann; Justin M. Balko; Ben Park; Brent N. Rexer; Ingrid A. Mayer; Carlos L. Arteaga |
| Publication Year: | 2025 |
| Subject Terms: | Cancer; Therapeutic Research and Development; Clinical Research and Trials; Breast Cancer; Clinical Trial Results; Phase I clinical trials; Drug Targets; Protein kinase & phosphatase drug targets |
| Description: | Supplemental tables and figures |
| Document Type: | article in journal/newspaper |
| Language: | unknown |
| DOI: | 10.1158/1078-0432.30029555 |
| Availability: | https://doi.org/10.1158/1078-0432.30029555; https://figshare.com/articles/journal_contribution/Supplementary_Data1_from_Phase_Ib_Trial_of_Fulvestrant_Palbociclib_and_Erdafitinib_a_pan-FGFR_Tyrosine_Kinase_Inhibitor_in_HR_HER2_Metastatic_Breast_Cancer/30029555 |
| Rights: | CC BY |
| Accession Number: | edsbas.72F3A99F |
| Database: | BASE |